Elmwood Wealth Management Inc. Purchases Shares of 585 Eli Lilly and Company (NYSE:LLY)

Elmwood Wealth Management Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 585 shares of the company’s stock, valued at approximately $518,000.

A number of other hedge funds have also made changes to their positions in LLY. Capital Planning LLC acquired a new position in shares of Eli Lilly and Company during the first quarter worth about $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $6,916,000. M&G Plc acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $9,878,000. Finally, Leo Wealth LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $3,355,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Guggenheim lifted their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Barclays increased their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Bank of America lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $979.29.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $1.89 during trading on Monday, hitting $930.17. 602,079 shares of the stock were exchanged, compared to its average volume of 2,997,299. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock’s fifty day moving average is $910.84 and its 200 day moving average is $853.38. The stock has a market cap of $884.04 billion, a PE ratio of 137.44, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.